Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters

Mostrar otras versiones (1)

BACKGROUND AND OBJECTIVES: B-cell-depleting therapies may affect the development of a protective immune response following vaccination against SARS-CoV-2. It is important to have a different strategy for creating immunity in this patient population. The objective of this study was to evaluate whethe...

Descripción completa

Detalles Bibliográficos
Autores principales: Conte, William L., Golzarri-Arroyo, Lilian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123743/
https://www.ncbi.nlm.nih.gov/pubmed/35661563
http://dx.doi.org/10.1016/j.msard.2022.103905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123743/
https://www.ncbi.nlm.nih.gov/pubmed/35661563
http://dx.doi.org/10.1016/j.msard.2022.103905

Ejemplares similares